IPO Advisory
In-depth, experienced and seamless execution throughout the IPO Process.
IPO Detail
IPO Information
Financial
Financial Report
Peer Comparison
Peer Comparison
Performance
Performance Report
IPO Review
IPO Review
Aptus Pharma caters to the Pharmaceutical sector, the Indian pharmaceutical industry logged a compound annual growth rate (CAGR) of 6- 8%, primarily driven by an 8% increase in exports and a 6% rise in the domestic market. Exports of drugs and pharmaceuticals recorded a strong y-o-y growth of 9.7% during April-March FY24.
India has emerged as the medial tourism hub of the world providing cost-effective treatments with the latest technology enabled by several pathbreaking reforms and provisions in healthcare sector. Indian pharmaceutical industry is known for its generic medicines and low-cost vaccines globally. Indian drugs are exported to more than 200 countries in the world, with the US as the key market.
| Revenue | ₹17.85 cr | ₹24.55 cr (+37.54%) | |
| PAT | ₹0.79 cr | ₹3.09 cr (+291.14%) | |
| PAT Margin | 4.43 % | 12.59 % (+184.20%) | |
| EBITDA | ₹1.49 cr | ₹4.75 cr (+218.79%) | |
| EBITDA Margin | 8.35 % | 19.35 % (+131.74%) | |
| ROE | 44.63 % | 44.40 % (-0.52%) | |
| ROCE | 21.70 % | 45.66 % (+110.41%) | |
| D/E | 3.00 | 1.49 (-50.33%) |
The product portfolio is structured across four distinct divisions to ensure focused marketing and efficient coverage of therapeutic segments: Aptus Pharma (Pioneer Division), Aptus CD Care (Cardiac Diabetic Division), Aptus Wellcare (Wellcare Division) and Aptus Global (Export Division). As on March 31, 2025, the product basket comprises of 194 pharmaceutical formulations in more than eleven (11) therapeutic segments. The company has established presence across two states in India—Gujarat and West Bengal.
PE Ratio: 15.49x Average Sector PE Ratio: 20.39x
| QIB Shares Offered: | 880000 |
| - Anchor Investor Shares Offered: | 528000 |
| − QIB (Ex. Anchor) Shares Offered : | 352000 |
| NII (HNI) Shares Offered: | 266000 |
| - bNII > ₹10L: | 178000 |
| - sNII < ₹10L: | 88000 |
| Retail Shares Offered: | 620000 |
| Total Shares Offered: | 1766000 |
| Application | Lot | Shares | Amount |
|---|---|---|---|
| Individual investors (Retail) (Max) | 2 | 4000 | ₹280000 |
| S-HNI (Min) | 3 | 6000 | ₹420000 |
| S-HNI (Max) | 7 | 14000 | ₹980000 |
| B-HNI (Min) | 8 | 16000 | ₹1120000 |
Avg IPO Size (Sector Based):
₹ 21.71 cr.
Average Sector PE Ratio:
20.39 X
Listing Price:
₹ 80.80
Aptus Pharma is engaged in the business of marketing, and distribution of finished pharmaceutical formulations. While the Company does not own any manufacturing facilities, it operates through a contract manufacturing model. They do not own any manufacturing plants but has entered into contract manufacturing agreement with seven manufacturing units. under various arrangements. Of these, they have formal loan and license agreements in place with two manufacturing units. The remaining production is carried out through informal arrangements with Other manufacturers, based on purchase orders (PO). They provide a diverse range of pharmaceutical products catering to various therapeutic categories including anti-infectives, gastrointestinal, antacids, anti-allergic and respiratory, nutritional supplements, pain management, neuro-psychiatric, cardiovascular, anti-diabetic, lipidlowering, and general wellness products. These are offered across a variety of dosage forms, such as tablets, capsules, softgels, syrups, suspensions, injections, ointments, creams, balms, drops, lotions, vials, powders, gels, and sachets.
Diversified Product Portfolio
Robust and Responsive Distribution Network
Strategic Manufacturing Alliance
Competitive and Cost-Effective Pricing
Exposed to regulatory permits and approvals
Interactive Financial Services Limited, based in Ahmedabad is the Lead Manager (BRLM) of Aptus Pharma IPO. Interactive Financial Services Limited has handled (17) SME IPOs till date of which (76%) of the SME IPOs have been listed with listing gains. Read full review of Interactive Financial Services Limited .
Aptus Pharma IPO may offer opportunites, depending on your investment strategy. For in-depth analysis, risk factors, and KPIs, check our detailed report on Aptus Pharma Financial Review Page
Merchant Banker(s) of Aptus Pharma IPO: Interactive Financial Services Limited
Aptus Pharma IPO subscription was 22.27 X. IPO subscription refers to applications received in an IPO by each quota, i.e., QIB, Retail, and NII. In some IPOs, Eligible employee quota and shareholder’s quota are also present. Learn more about IPO subscriptions here.
Aptus Pharma IPO listed at a listing price of 80.80 against the offer price of 70.00.
The current market price of Aptus Pharma is 88.32.
Why Us?
